FDA Approves Efgartigimod as New Treatment for Chronic Inflammatory ...
Jun 21, 2024 · The FDA has approved Argenx's coformulation therapy efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo) as a new treatment for adults with chronic inflammatory demyelinating polyneuropathy (CIDP).
Subcutaneous Efgartigimod PH20 Efficacious in Patients With CIDP ...
Oct 20, 2024 · A recent analysis of the phase 3 ADHERE trial demonstrated the clinical benefit of subcutaneous efgartigimod PH20 in patients with chronic inflammatory demyelinating polyneuropathy.
Chronic Inflammatory Demyelinating Polyneuropathy
In honor of Chronic Demyelinating Polyneuropathy Awareness Month, held May 2024, get caught up on some of the latest news in CIDP, with data updates and expert insights all in one place from the NeurologyLive® team.
Chronic Inflammatory Demyelinating Polyneuropathy: A …
Jul 25, 2024 · CIDP is an immune-mediated, inflammatory, peripheral disorder, known to affect the myelin sheaths (ie, the fatty coverings on the nerves). Besides progressive weakening of the arms and legs, symptoms can include numbness, tingling, impaired balance, and …
Halozyme Announces argenx's VYDURA with ENHANZE® was …
Dec 30, 2024 · Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy News provided by Halozyme Therapeutics, Inc.
FDA Approves Drug for Chronic Inflammatory Demyelinating Polyneuropathy
Adults with chronic inflammatory demyelinating polyneuropathy (CIDP) now have a new treatment option, thanks to the US Food & Drug Administration's (FDA) June 24 approval of efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo).
Vyvgart Hytrulo Approved for Chronic Inflammatory Demyelinating ...
Jun 24, 2024 · The Food and Drug Administration (FDA) has approved Vyvgart ® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adults with chronic inflammatory demyelinating...
argenx Announces Approval of VYVDURA (efgartigimod alfa and
Dec 27, 2024 · About Chronic Inflammatory Demyelinating Polyneuropathy. Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare and serious autoimmune disease of the peripheral nervous system ...
Chronic Inflammatory Demyelinating Polyneuropathy - Rare …
We explore growing evidence of a link between COVID-19 vaccination and newly developed immune-mediated neuropathies. This article presents 3 rare cases of atypical chronic inflammatory demyelinating polyneuropathy (CIDP) showing cranial nerve involvement.
CIDP Is Misdiagnosed at an Alarming Rate, Due to a Confluence of ...
Feb 16, 2024 · In the intricate landscape of chronic inflammatory demyelinating polyneuropathy (CIDP), the burden of misdiagnosis casts a long and harrowing shadow over the lives of patients knowingly—or unknowingly—affected by it.